Target intelligence / Profile preview

Nuclear envelope (NE)

Target
NE
Molecular classification
Cellular organelle, Double-membrane system, Nuclear lamina, Nuclear pore complex
01

Overview

The nuclear envelope (NE) is a highly regulated double-membrane structure that separates the nucleus from the cytoplasm in eukaryotic cells. It consists of the inner and outer nuclear membranes, which are perforated by nuclear pore complexes (NPCs) that govern the selective exchange of proteins and RNA (doi:10.1038/nrm.2017.93). Beneath the inner membrane lies the nuclear lamina, a proteinaceous meshwork primarily composed of lamins that provides mechanical stability and organizes chromatin (doi:10.1101/cshperspect.a011130). In disease, mutations in NE components—collectively known as laminopathies—lead to premature aging, muscular dystrophies, and cardiomyopathies. From a therapeutic perspective, the NE is a critical site for drug action; for example, Selinexor targets the nuclear export protein XPO1 located at the NE to retain tumor-suppressor proteins within the nucleus of cancer cells (doi:10.1186/s13045-018-0603-z). Additionally, the drug Lonafarnib is used to treat Hutchinson-Gilford progeria syndrome by preventing the abnormal farnesylation and subsequent membrane anchoring of progerin, a mutant form of lamin A (doi:10.1001/jama.2018.3120). While essentially a cellular organelle rather than a single molecular target, its components represent vital nodes for clinical intervention in oncology and genetic disorders.

Other names
Nuclear membraneNucleolemmaKaryothecaPerinuclear envelope
02

Biological functions

Nucleocytoplasmic transportChromatin organizationGenome stabilityMechanical supportGene expression regulationSignal transduction
03

Disease associations

Hutchinson-Gilford progeria syndromeEmery-Dreifuss muscular dystrophyDilated cardiomyopathyCancerRestrictive dermopathyLipodystrophy
04

Safety considerations

Systemic toxicity due to disruption of essential nucleocytoplasmic transportHematological adverse effects (e.g., thrombocytopenia, neutropenia)Gastrointestinal distressPotential for DNA damage and genomic instability
05

Interacting drugs

Selinexor

4 more in the full profile.

06

Biomarkers

Lamin A/C mutations (LMNA)XPO1 expression levelsProgerin protein levelsNuclear morphology (blebbing)

Beyond the preview

Go deeper on Nuclear envelope (NE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear envelope (NE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call